Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

629
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
629
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

983
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
983
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

583
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
583
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.6K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of the P2X<sub>3</sub> Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study.

Journal of asthma and allergy·2026
Same author

Can tiotropium add-on inhalation revolutionize therapy in elderly asthmatic patients? A treatable traits approach towards successful aging.

International journal of clinical pharmacology and therapeutics·2026
Same author

Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2024
Same author

Current Status and Challenges in Delivering Comprehensive Care for Patients with Hemophilia.

Journal of blood medicine·2023
Same author

Efficacy of Gefapixant, a P2X<sub>3</sub> Antagonist, for Refractory Atopic Cough.

International medical case reports journal·2023
Same author

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.

International journal of hematology·2023

Related Experiment Video

Updated: Apr 2, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

9.6K

Microparticle and Atherothrombotic Diseases.

Shosaku Nomura1

  • 1First Department of Internal Medicine, Kansai Medical University.

Journal of Atherosclerosis and Thrombosis
|September 29, 2015
PubMed
Summary
This summary is machine-generated.

Microparticles (MPs), small vesicles from cells, are linked to thrombotic diseases. Elevated MPs may serve as a valuable biomarker for identifying atherothrombosis.

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.8K

Related Experiment Videos

Last Updated: Apr 2, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

9.6K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.8K

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pathophysiology

Background:

  • Microparticles (MPs) are cell-derived membrane vesicles released during activation or apoptosis.
  • MPs express phospholipids, contributing to procoagulant activity.
  • Elevated levels of MPs from platelets, endothelial cells, and monocytes are common in thrombotic diseases.

Purpose of the Study:

  • To review the multifaceted roles of MPs beyond their procoagulant activity.
  • To explore the diagnostic potential of MPs in various clinical disorders.
  • To assess the utility of MPs as biomarkers for atherothrombosis.

Main Methods:

  • Literature review of studies on microparticle origin, composition, and function.
  • Analysis of data linking circulating MP levels to thrombotic diseases.
  • Evaluation of evidence for MP involvement in clinical disorders.

Main Results:

  • MPs exhibit diverse functions beyond procoagulant activity.
  • Circulating MP levels vary based on disease type, state, and treatment.
  • Increased MPs are implicated in numerous clinical disorders.

Conclusions:

  • Microparticles have expanded roles in physiology and pathology.
  • MPs show promise as diagnostic and prognostic biomarkers.
  • Evidence suggests MPs are useful biomarkers for identifying atherothrombosis.